Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/165803PRODUCTION APPARATUS AND PRODUCTION METHOD FOR SUCROSE-6-ESTER
WO 11.08.2022
Int.Class B01D 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
DSEPARATION
3Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
Appl.No PCT/CN2021/075813 Applicant ANHUI JINHE INDUSTRIAL CO., LTD. Inventor ZHANG, Zhengsong
A production apparatus and a production method for sucrose-6-ester, the apparatus comprising a tank, a rotary distillation device, and a condensing device, wherein the tank comprises a separation cavity and a reaction cavity, the condensing device is sleeved in the rotary distillation device, and the rotary distillation device is slidably connected in the separation cavity; a turntable for rotary distillation is fixed on a top surface of a rotating drum by a plurality of connecting plates, and a first heating device is provided on an outer wall of the turntable; the condensing device comprises a condensing pipe, a water-receiving plate and a water-condensing water tank, which are vertically connected in sequence; the condensing device is sleeved in the rotating drum of the rotary distillation device in a non-contact manner, and the condensing pipe runs through the turntable to be in contact with a top surface of the tank; and the rotary distillation device can rotate about a central axis of the turntable, so as to separate a reaction liquid entering from a reaction liquid feed pipe into steam and residual liquid after distillation. The apparatus realizes continuous production of sucrose-6-ester, greatly shortens the production cycle and improves the production efficiency.
2.WO/2022/167456ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION
WO 11.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2022/052417 Applicant F. HOFFMANN-LA ROCHE AG Inventor FUNDER, Erik
The present invention relates to enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity. The invention, in particular, relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention, in particular, relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
3.WO/2022/166581NUCLEOTIDE DERIVATIVE, PHARMACEUTICAL COMPOSITE THEREOF AND USE THEREOF
WO 11.08.2022
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
Appl.No PCT/CN2022/072689 Applicant SHIJIAZHUANG DISCOVERY MEDICINE TECHNOLOGY CO., LTD Inventor ZHANG, Zhefeng
A nucleotide derivative, a pharmaceutical composition thereof, and a use thereof. Specifically disclosed are a nucleotide derivative represented by formula (I) or a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug for treating cardiovascular and cerebrovascular diseases, wherein the definition of groups in formula (I) is detailed in the description.
4.WO/2022/168846BARRIER FUNCTION IMPROVER
WO 11.08.2022
Int.Class A61K 31/7034
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
Appl.No PCT/JP2022/003962 Applicant SHOWA DENKO K.K. Inventor NAKAGAMI Yuko
A barrier function improver which contains methylhesperidin as an active ingredient, and a barrier function improver composition which contains said barrier function improver and a pharmaceutically acceptable carrier.
5.WO/2022/169855CHITIN ANALOGS FOR THE TREATMENT OF KIDNEY DISEASES
WO 11.08.2022
Int.Class A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
Appl.No PCT/US2022/014919 Applicant AYUVIS RESEARCH, INC. Inventor ACHARYA, Suchismita
The present invention includes compositions and methods for preventing or treating a patient for kidney injury comprising administering an effective amount of a compound of Formula I: where n = 0-5; X = NH, O, S, or CH2; Y = phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, or aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R = H, C(O)R2, SO2R2; R1 = H, C(O)R2, SO2R2; R2 = ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4 = ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl; and Z = NH, O, S, CH2 or none.
6.WO/2022/165838SYNTHESIS APPARATUS, SYNTHESIZER AND SYNTHESIS METHOD
WO 11.08.2022
Int.Class B01J 19/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
19Chemical, physical or physico-chemical processes in general; Their relevant apparatus
Appl.No PCT/CN2021/076015 Applicant BGI SHENZHEN Inventor HU, Dinglong
Provided is a synthesis apparatus for synthesizing biomacromolecules. The synthesis apparatus is used for synthesizing biomacromolecules, and comprises a feeding apparatus, a recognition apparatus, a reaction apparatus, a sorting apparatus and a transfer apparatus, wherein the feeding apparatus comprises a conveying assembly that is capable of conveying a plurality of biochips at the same time; the recognition apparatus is used for recognizing identifiers of the biochips on the conveying assembly and feeding back generated identification information to a control apparatus; the reaction apparatus comprises a plurality of reaction containers, the reaction containers being used for performing a synthesis reaction on the biochips; the sorting apparatus comprises a plurality of first sorting assemblies, which are located on a side face of a conveying apparatus and respectively correspond to the plurality of reaction containers, the plurality of first sorting assemblies being used for sorting, under the control of the control apparatus, the plurality of biochips located on the conveying assembly to the reaction containers corresponding to current synthesis reactions of the biochips; and the transfer apparatus is used for transferring the biochips in the reaction containers to the feeding apparatus. Further provided are a synthesizer and a synthesis method.
7.WO/2022/168106CHEMO-ENZYMATIC PROCESS FOR SYNTHESIS OF MOLNUPIRAVIR
WO 11.08.2022
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
Appl.No PCT/IN2021/050456 Applicant FERMENTA BIOTECH LIMITED Inventor DATLA, Anupama
Disclosed herein is a process for synthesis of Molnupiravir from cytidine of using a lipase for esterification reaction. The process comprises of reacting compound of formula II with acetone in presence of sulphuric acid to obtain compound of formula III; enzymatically converting compound of Formula III to compound of Formula IV, and Hydroxyaminating Formula IV using Hydroxyl amine sulphate or hydrochloride followed by deprotection to obtain compound of formula I
8.WO/2022/168107ENZYMATIC SYNTHESIS OF MOLNUPIRAVIR INTERMEDIATE
WO 11.08.2022
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
Appl.No PCT/IN2021/050490 Applicant FERMENTA BIOTECH LIMITED Inventor DATLA, Anupama
Disclosed herein is the enzymatic process for synthesis of Molnupiravir intermediate, 5'-isobutylester of cytidine acetonide. The process employs cytidine acetonide as starting material to prepare 5'-isobutylester of cytidine acetonide. The esterification of cytidine acetonide is carried out using Enzyme CAL B expressed in Pichia pastoris. The present invention further discloses processes for preparation of O-Isobutyl acetone oxime.
9.4039809COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
EP 10.08.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 21212946 Applicant ALNYLAM PHARMACEUTICALS INC Inventor QUERBES WILLIAM
The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HAO1 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
10.4039278OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION
EP 10.08.2022
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
Appl.No 22162215 Applicant ALNYLAM PHARMACEUTICALS INC Inventor MANOHARAN MUTHIAH
The present invention relates to ligand conjugates of oligonucleotides (e.g., iRNA agents). The ligands are derived primarily from monosaccharides These conjugates are useful for the in vivo delivery of oligonucleotides.